GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » BioPlus Acquisition Corp (NAS:BIOSW) » Definitions » Common Stock

Switch to:

BioPlus Acquisition (BioPlus Acquisition) Common Stock : $138.43 Mil (As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is BioPlus Acquisition Common Stock?

BioPlus Acquisition's quarterly common stock increased from Dec. 2022 ($237.78 Mil) to Mar. 2023 ($240.37 Mil) but then declined from Mar. 2023 ($240.37 Mil) to Jun. 2023 ($138.43 Mil).

BioPlus Acquisition's annual common stock increased from . 20 ($0.00 Mil) to Dec. 2021 ($234.60 Mil) and increased from Dec. 2021 ($234.60 Mil) to Dec. 2022 ($237.78 Mil).

BioPlus Acquisition Common Stock Historical Data

The historical data trend for BioPlus Acquisition's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioPlus Acquisition Common Stock Chart

BioPlus Acquisition Annual Data

Trend

Dec21

Dec22

Common Stock

234.60

237.78

BioPlus Acquisition Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Common Stock	Get a 7-Day Free Trial					234.94	235.89	237.78	240.37	138.43

BioPlus Acquisition Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

BioPlus Acquisition (BioPlus Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » BioPlus Acquisition Corp (NAS:BIOSW) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

260 Madison Avenue, Suite 800, New York, NY, USA, 10026

Website

BioPlus Acquisition Corp is a blank check company.

BioPlus Acquisition (BioPlus Acquisition) Headlines

From GuruFocus

Avertix's Guardian� System, First and Only FDA-Approved Implantable Heart Attack Detection and Warning System, Now Available at AdventHealth Orlando

By sperokesalga sperokesalga • 06-13-2023

Renown Cardiologist and Professor Ian T. Meredith, MD to Join Avertix Medical's Board of Directors

By Marketwired • 07-17-2023

Avertix and BIOS Acquisition Corporation Mutually Agree to Terminate Proposed Business Combination

By Marketwired • 10-04-2023

BioPlus Acquisition Corp. Announces Pricing of Upsized $200,000,000 Initial Public Offering

By GuruFocusNews GuruFocusNews • 12-06-2021

Heart & Rhythm Institute of Trinity and Avertix Announce Partnership to Improve Cardiac Care and Patient Monitoring

By Marketwired • 08-16-2023

BioPlus Acquisition Corp. Announces Termination of Business Combination Agreement with Avertix Medical, Inc. and its Intention to Liquidate

By Marketwired • 10-04-2023

Avertix, Maker of First and Only FDA-Approved Implantable Heart Attack Warning System, to Become Publicly Traded via Merger with BIOS Acquisition Corporation

By sperokesalga sperokesalga • 05-03-2023

Home About Jobs Site Map Term of Use Privacy Policy Mobile App Referral Program Partner Program FAQ Contact Us 中文 All-In-One Screener
Stock List Guru List Insider List Insider Trade Economic Indicators Industry Data DCF Calculator Discussion Board Plans Excel Add-In Google Sheets Add-on
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.